Antipsychotics prescription and cerebrovascular events in italian older persons

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 542-545

  Franchi, Carlotta ^a   Sequi, Marco ^a   Tettamanti, Mauro ^a   Bonometti, Francesca ^b   Nobili, Alessandro ^a   Fortino, Ida ^c   Bortolotti, Angela ^c   Merlino, Luca ^c   Pasina, Luca ^a   Djade, Codjo Djignefa ^a   Marengoni, Alessandra ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Regional Health Ministry   (Italy)

Author keywords

acetylcholinesterase inhibitors; antipsychotic drugs; cerebrovascular events; older persons

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT;

AGED; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG USE; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; ITALY; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYPHARMACY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84879841497     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182968fda     Document Type: Article

References (26)

1. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised double-blind trial. J Clin Psychiatry. 1999;60:107-115.
2. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68(2):190-197.
3. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134-143.
4. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167(11):1269-1270.
5. Food and Drug Administration Web site. Transcript for FDA Media Briefing on Safety Labeling Changes for Antipsychotic Drugs June 16, 2008. Available at: http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/UCM169331.pdf. Accessed June 24, 2010.
6. Food and Drug Administration Web site. US Department of Health and Human Services. Public Health Advisory: Deaths with antipsychotics in Elderly Patients With Behavioral Disturbances.2005. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171. htm. Accessed December 4, 2010.
7. Franchi C, Tettamanti M, Marengoni A, et al. Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur Neuropsychopharmacol. 2012;22(8):569-577.
8. Mazzucco S, Cipriani A, Lintas C, et al. Effect of antipsychotic drugs on cerebrovascular morbidity and mortality: a systematic review. Curr Drug Ther. 2006;1(3):241-248.
9. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19:91-103.
10. Pratt N, Roughead EE, Salter A, et al. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol. 2012;12:72.
11. Sacchetti E, Trifirò G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective color study including unexposed subjects. J Psychopharmacol. 2008;2(1):39-46.
12. Barnett MJ,Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27(6):595-601.
13. Nobili A, Franchi C, Pasina L, et al. Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-Elderly Project. Pharmacoepidemiol Drug Saf. 2011;20:488-496.
14. Percudani M, Barbui C, Fortino I, et al. Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord. 2004;83:169-175.
15. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification. About the ATC/ DDD system. Available at: http://www.whocc.no/atcddd/. Accessed June 24, 2010.
16. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic and risk for ischemic stroke: population based retrospective cohort study. BMJ. 2005;330(7489):445.
17. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic study using claims data. Am J Epidemiol. 2011;154:854-864.
18. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
19. Mayo V, Yuen E, Rabinowitz C, et al. Using pharmacy data to identify those with chronic conditions in Emilia Romagna, Italy. J Health Serv Res Policy. 2005;10:232-238.
20. Mehta S, Johnson ML, Chen H, et al. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. J Clin Psychiatry. 2010;71(6):689-698.
21. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
22. Kamijo Y, Soma K, Nagai T, et al. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenotiazines. Circ J. 2003;67:46-48.
23. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. JAMDA. 2004;2:129-132.
24. Ballard C, Oyebode F. Psychotic symptoms in patients with dementia. Int J Geriatr Psychiatry. 1995;10:743-752.
25. Mittal V, Kurup L, Williamson D, et al. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2001;26:10-28.
26. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of the evidence. JAMA. 2005;293:596-608.